Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Annette Hanson, MD, Ron Pies, MD, and Mark Komrad, MD
Authors respond to “How Should Physicians Care for Dying Patients with Amyotrophic Lateral Sclerosis?” by arguing that patients’ motives for accessing death with dignity laws should be thoroughly explored and that temporarily limiting patient autonomy can promote well-being at the end of life.
AMA J Ethics. 2018;20(11):E1107-1109. doi:
10.1001/amajethics.2018.1107.
Alexander Craig, MPhil and Elizabeth Dzeng, MD, PhD, MPH
Responding to “Added Points of Concern about Caring for Dying Patients,” authors argue that physicians’ refusal to prescribe lethal drugs in accordance with states’ death with dignity laws could damage patient-physician relationships and harm patients.
AMA J Ethics. 2018;20(11):E1110-1112. doi:
10.1001/amajethics.2018.1110.
Health care reform expanded health insurance to millions, but current community benefit policies must be used by organizations hoping to address social determinants.
AMA J Ethics. 2019;21(3):E248-258. doi:
10.1001/amajethics.2019.248.
The Asilomar Conference of 1975 and the German Ethics Council offer guidance for a path towards prudent regulation in the face of unknown and significant risks.
AMA J Ethics. 2019;21(12):E1042-1048. doi:
10.1001/amajethics.2019.1042.